Reston, VA—The Journal of Nuclear Medicine (JNM)—the flagship publication of the Society of Nuclear Medicine and Molecular Imaging—has maintained its status as one of the top medical imaging journals worldwide, according to new data just released in Clarivate’s 2023 Journal Citation Reports. With an impact factor of 9.1, JNM saw increases in its five-year impact factor, journal citation indicator, and article influence score, among other categories.
“This is an exciting time for nuclear medicine, with ground-breaking advances in molecular imaging, theranostics, artificial intelligence, and other areas,” said Johannes Czernin, MD, JNM editor-in-chief and professor of molecular and medical pharmacology and chief of the Ahmanson Translational Theranostics Division at the UCLA David Geffen School of Medicine, Los Angeles, California.
Of 204 medical imaging journals included in the Clarivate report, JNM ranked sixth overall. JNM’s journal citation indicator (JCI) achieved its highest rating to date, jumping from 2.59 to 2.98 percent. The JCI is a single score given to each journal based on normalized citations across three full years of citation data. As average performance is set to 1.0, JNM’s JCI rating of 2.98 percent means the journal performed close to three times better than average. In addition, the journal’s five-year impact factor increased from 9.0 to 9.1, and the article influence score rose from 2.257 to 2.606. The normalized Eigenfactor score also increased from 5.7023 to 6.11.
“The JNM editorial team is very intentional in the articles that it chooses for publication in the journal,” notes Czernin. “By keeping our pulse on advances in the field and adhering to rigorous quality standards, we strive to make the journal an invaluable resource for the nuclear medicine and molecular imaging field. I applaud the entire team, from the associate editors and reviewers to SNMMI Publications Committee to journal staff for their contributions to JNM.”
Visit the JNM website for the latest research, and follow our new Twitter and Facebook pages @JournalofNucMed or follow us on LinkedIn.
Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or rmaxey@snmmi.org.
###
About JNM and the Society of Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed more than 16 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.
Reston, VA—The Journal of Nuclear Medicine (JNM)—the flagship publication of the Society of Nuclear Medicine and Molecular Imaging—has maintained its status as one of the top medical imaging journals worldwide, according to new data just released in Clarivate’s 2023 Journal Citation Reports. With an impact factor of 9.1, JNM saw increases in its five-year impact factor, journal citation indicator, and article influence score, among other categories.
“This is an exciting time for nuclear medicine, with ground-breaking advances in molecular imaging, theranostics, artificial intelligence, and other areas,” said Johannes Czernin, MD, JNM editor-in-chief and professor of molecular and medical pharmacology and chief of the Ahmanson Translational Theranostics Division at the UCLA David Geffen School of Medicine, Los Angeles, California.
Of 204 medical imaging journals included in the Clarivate report, JNM ranked sixth overall. JNM’s journal citation indicator (JCI) achieved its highest rating to date, jumping from 2.59 to 2.98 percent. The JCI is a single score given to each journal based on normalized citations across three full years of citation data. As average performance is set to 1.0, JNM’s JCI rating of 2.98 percent means the journal performed close to three times better than average. In addition, the journal’s five-year impact factor increased from 9.0 to 9.1, and the article influence score rose from 2.257 to 2.606. The normalized Eigenfactor score also increased from 5.7023 to 6.11.
“The JNM editorial team is very intentional in the articles that it chooses for publication in the journal,” notes Czernin. “By keeping our pulse on advances in the field and adhering to rigorous quality standards, we strive to make the journal an invaluable resource for the nuclear medicine and molecular imaging field. I applaud the entire team, from the associate editors and reviewers to SNMMI Publications Committee to journal staff for their contributions to JNM.”
Visit the JNM website for the latest research, and follow our new Twitter and Facebook pages @JournalofNucMed or follow us on LinkedIn.
Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or rmaxey@snmmi.org.
###
About JNM and the Society of Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed more than 16 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.
JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org.
